Treatment of acquired severe aplastic anemia with antilymphocyte globulin, cyclosporin A, methyprednisolone, and granulocyte colony-stimulating factor

American Journal of Hematology

Volumn 82, Issue 9, 2007, Pages 783-786

  Dinçol, Günçaǧ ^a,b   Aktan, Melih ^a   Diz Küçükkaya, Reyhan ^a   Yavuz, Selim ^a   Nalçaci, Meliha ^a   Öztürk, Şükrü ^a   Palanduz, Şükrü ^a   Doǧan, Öner ^a   Aǧan, Mehmet ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; CYCLOSPORIN; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; BONE MARROW APLASIA; CHROMOSOME ANALYSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; ANIMAL; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; HORSE; MIDDLE AGED; MORTALITY; NEUTROPHIL; RECURRENT DISEASE; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANEMIA, APLASTIC; ANIMALS; ANTILYMPHOCYTE SERUM; CYCLOSPORINE; FEMALE; GLUCOCORTICOIDS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HORSES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; NEUTROPHILS; RECURRENCE; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 35748977951     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20954     Document Type: Article

References (33)

1. Brodsky RA, Jones RJ. Aplastic anaemia. Lancet 2005;365:1647-1656.
2. Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med 1997;336:1365-1372.
3. Young NS. Acquired aplastic anemia. Ann Int Med 2002;136:534-546.
4. Deeg HJ, Leisenring W, Storb R, et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood 1998;91:3637-3645.
5. Bacigalupo A, Oneto R, Bruno B, et al. Report of the European Group for Blood and Marrow transplantation. On behalf of the Working Party on Severe Aplastic Anemia of the European Group for Blood and Marrow Transplantation. Current results of bone marrow transplantation in patients with acquired severe aplastic anemia. Acta Haematol 2000;103:19-25.
6. Marsh JC, Hows JM, Bryett KA, Al-Hashimi S, Fairhead SM, Gordon-Smith EC. Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity. Blood 1987;70:1046-1052.
7. Young N, Griffith P, Brittain E, et al. A multicenter trial of antithymocyte globulin in aplastic anemia and related diseases. Blood 1988;72:1861-1869.
8. Leonard EM, Raefsky E, Griffith P, Kimball J, Nienhuis AW, Young NS. Cyclosporine therapy of aplastic anaemia, congenital and acquired red cell aplasia. Br J Haematol 1989;72:278-284.
9. Gluckman E, Esperou-Bourdeau H, Baruchel A, et al. Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia. Blood 1992;79:2540-2546.
10. Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. For The German Aplastic Anemia Study Group. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. N Engl J Med 1991;324:1297-1304.
11. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H, For The German Aplastic Anemia Study Group. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003;101:1236-1242.
12. Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood 1995;85:3058-3065.
13. Rosenfeld S, Follman D, Nunez O, Young NS. Antithymocyte globulin and cyclosporin or severe aplastic anemia, association between hematologic response and long-time outcome. JAMA 2003;289:1130-1135.
14. Bacigalupo A, Broccia G, Corda G, et al. Gluckman for the European Group for Blood and Marrow Transplantation (EBMT) Working Party In SAA. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): A pilot study of the EBMT SAA Working Party. Blood 1995;85:1348-1353.
15. Bacigalupo A, Bruno B, Saracco P, et al. For the European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. Blood 2000;95:1931-1934.
16. Marsh JC, Socie G, Schrezenmeier H, et al. For the European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia. Haemopoietic growth factors in aplastic anaemia: A cautionary note. Lancet 1994;344:172-173.
17. Gluckman E, Rokicka-Milewska R, Hann I, et al. For the European Group for Blood and Marrow Transplantation Working Party for Severe Aplastic Anemia. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol 2002;119:1075-1082.
18. Camitta BM, Thomas ED, Nathan DG, et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood 1979;53:504-514.
19. Bacigalupo A, Hows J, Gluckman E, et al. For the EBMT Working Party of Severe Aplastic Anemia. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): A report of the EBMT SAA working party. Br J Haematol 1988;70:177-182.
20. Schrezenmeier H, Hertenstein B, Wagner B, Raghavachar A, Heimpel H. A pathogenetic link between aplastic anemia and paroxysmal nocturnal hemoglobinuria is suggested by a high frequency of aplastic anemia patients with a deficiency of phosphatidylinositol glycan anchored proteins. Exp Hematol 1995;23:81-87.
21. Dacie JV, Lewis SM. Practical Haematology, 6th ed. London: Churchill Livingstone; 1984. p201.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-460.
23. Dincol G, Saka B, Aktan M, et al. Very severe aplastic anemia following resection of lymphocytic thymoma: Effectiveness of antilymphocyte globulin, cyclosporin A, and granulocyte-colony stimulating factor. Am J Hematol 2000;64:78-79.
24. Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 2002;99:3129-3135.
25. Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A. Late clonal diseases of treated aplastic anemia. Semin Hematol 2000;37:91-101.
26. De Lord C, Tooze JA, Saso R, Marsh JC, Gordon-Smith EC. Deficiency of glycosylphosphatidyl inositol-anchored proteins in patients with aplastic anaemia does not affect response to immunosuppressive therapy. Br J Haematol 1998;101:90-93.
27. Maciejewski JP, Rivera C, Kook H, Dunn D, Young NS. Relationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol-anchored protein-deficient clones. Br J Haematol 2001;115:1015-1022.
28. Socie G, Henry-Amar M, Bacigalupo A, et al. For the European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med 1993;329:1152-1157.
29. Najean Y, Haguenauer O,For the Cooperative Group for the Study of Aplastic and Refractory Anemias. Long-term (5 to 20 years) Evolution of nongrafted aplastic anemias. Blood 1990;76:2222-2228.
30. Kaito K, Kobayashi M, Katayama T, et al. Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults. Br J Haematol 1998;103:297-303.
31. Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 1997;90:1009-1013.
32. Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood 2000;96:2049-2054.
33. Bacigalupo A, Brand R, Oneto R, et al. Treatment of acquired severe aplastic anemia: Bone marrow transplantation compared with immunosuppressive therapy - The European Group for Blood and Marrow Transplantation experience. Semin Hematol 2000;37:69-80.